In a strategic move to redefine drug safety monitoring, Tech Mahindra has partnered with NVIDIA to launch a cutting-edge pharmacovigilance (PV) solution driven by agentic AI and automation. This next-gen platform is designed to enhance accuracy, reduce turnaround times, and significantly lower operational costs in pharmacovigilance, marking a transformative leap from manual systems to intelligent automation.
Built on Tech Mahindra’s proprietary TENO framework and integrated with NVIDIA AI Enterprise software, the autonomous PV solution leverages tools like NVIDIA NeMo, NIM microservices, and AI Blueprints to streamline end-to-end workflows—from case intake to compliance management. At its core, the platform features large language model (LLM)-powered AI agents capable of autonomously classifying, prioritising, and validating adverse drug reaction (ADR) reports, eliminating human error and reducing processing delays.
The impact is measurable. The solution boasts up to 40% faster case turnaround, a 30% improvement in data accuracy, and 25% reduction in operational costs—all while ensuring strict regulatory compliance and timely risk response.
“As the pharmaceutical sector grapples with massive data volumes during trials and post-market surveillance, our alliance with NVIDIA enables intelligent, scalable pharmacovigilance,” said Nikhil Malhotra, Chief Innovation Officer & Global Head of AI and Emerging Technologies at Tech Mahindra.
With over 1,000 ADR cases managed daily for major drugs, the solution is a game-changer. For instance, when an ADR is reported via email, the AI agents instantly flag, categorise, and initiate the appropriate workflow—without any human intervention.
John Fanelli, Vice President of Enterprise Software at NVIDIA, added, “AI is ideally suited to monitor medicines throughout their lifecycle. This integration empowers pharmacovigilance teams with augmented intelligence to detect safety signals more effectively.”
Additionally, Tech Mahindra has extended its TENO framework with deeper integration of NVIDIA AI tools, including advanced generative AI pipelines and its VerifAI solution for data validation and governance. The system supports continuous learning and real-time model customisation, enabling adaptive decision-making as the pharmacovigilance landscape evolves.
This collaboration underscores a shared vision of transforming pharmacovigilance from reactive to predictive, ultimately contributing to safer medicines and better patient outcomes worldwide.